CannTrust Holdings Inc (TSX: TRST)(NYSE: CTST) has named Dr Len Walt, MD, MBA as its new chief medical officer, it was reported yesterday.
Dr Walt will lead the global medical function dedicated to strengthening the company's clinical research strategy, medical education programs, product innovation and support the expansion of CannTrust's global medical businesses and partnerships.
Dr Walt comes to CannTrust with extensive senior leadership experience in the pharmaceutical and biotechnology industries in Canada, USA and abroad. Most recently he held the position of vice president and head of Medical Affairs at Sobi Inc, where he led the company's North American medical and scientific operations. Previously, he held the position of medical director at Biogen Canada, where he built medical teams and developed relationships with key clinical investigators in Canada.
DuPont recognised with R&D 100 Award for innovation in healthcare
Synaptiq Therapeutics launches and acquires clinical-stage SYN-001 programme
WuXi AppTec named to FTSE4Good Index Series for fourth consecutive year
Kibow Biotech receives AANP Corporation of the Year Award
EDX Medical to provide molecular profiling services to Astron Health
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award